The first single-dose new crown vaccine is available Johnson & Johnson applies for emergency use license to the U.S. FDA

Instant International

Written by: Yang Qian

2021-02-05 08:11

The last update date: 2021-02-05 08:12

On February 4, Johnson & Johnson requested the US regulatory agency to authorize the use of the world’s first single-dose COVID-19 vaccine developed by it. The product is approximately 66% effective in preventing this virus. Therefore, it has been issued to US food The Drug Administration (FDA) has applied for emergency use authorization for its coronavirus vaccine.

If the application is approved, this will be the third Covid-19 vaccine approved for emergency use in the United States after Pfizer-BioNTech and Moderna.

US officials and Wall Street analysts wait and see that the Johnson & Johnson vaccine may be approved for use as early as this month.

Pfizer's vaccine was approved by the FDA on December 11 last year, and Moderna's vaccine was authorized a week later.

Unlike Pfizer and Moderna's vaccines that require two doses three or four weeks apart, Johnson & Johnson's vaccine only requires one dose, which simplifies the work of medical care.

The establishment of Johnson & Johnson and Reuters in 1886

US CNBC quoted Johnson & Johnson’s Chief Scientific Officer, Dr. Paul Stoffels, in a statement: “Today our single-shot COVID-19 vaccine application for emergency use authorization is a critical step towards reducing the global burden of disease and ending the pandemic.” The FDA submitted an application, and Johnson & Johnson also applied to health authorities around the world. After obtaining the authorization for the research COVID-19 vaccine for emergency use, it will start shipping immediately.

"We are working very urgently to provide the vaccine we developed to the public as soon as possible."

Johnson & Johnson said that based on the preliminary results of large-scale international studies, the vaccine is safe and provides strong protection against the moderate to severe COVID-19 virus. It is also easy to use and can ease the scarcity of drug supplies.

Johnson & Johnson released data on January 29 that its vaccine has an overall effectiveness rate of 66% in preventing Covid-19; its effectiveness against other variants is weaker, and its protection level against highly infectious strains of South Africa is only 57%.

According to CNN, before deciding whether to approve the third vaccine option in the United States, the Food and Drug Administration (FDA) will require independent consultants to publicly discuss all the data after a single dose of the vaccine.

The report quoted FDA vaccine director Dr. Peter Marks cautioning against making comparisons before the evidence is sufficient: “Due to the urgent need to control the pandemic, we cannot ignore any tool in the toolbox...We will do our best to ensure We find the people who benefit the most from each vaccine and deploy it in a very thoughtful manner."

New crown pneumonia丨The UK will implement hotel isolation and compulsory quarantine of passengers in high-risk areas from February 15

New crown vaccine 丨 ``zero confirmed'' North Korea has been allocated nearly 2 million doses of the first batch of Russian vaccines to arrive in Iran

New crown pneumonia丨U.S. intercepted nearly 13 million counterfeit masks in 2020

New crown pneumonia丨UK: There are about 4000 variant virus strains in the world, and pharmaceutical companies are improving vaccine response

01News

New crown pneumonia new crown vaccine